Érythème toxique à la chimiothérapie

Sibaud, V.

doi:10.1016/j.annder.2014.09.021

Cited by 6 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main side effects of this treatment are gastrointestinal and hematological toxicity [6]. It can also lead to some cutaneous events, such as alopecia, rash, pruritus, vitiligo-like lesions, or cutaneous lupus erythematosus [7,8]. To our knowledge, no case of DRESS syndrome with ribociclib has been published to date.…”

Section: Introductionmentioning

confidence: 99%

Case Report of Probable DRESS Syndrome Associated with Ribociclib

Carneiro,

Bove,

Beau-Salinas

et al. 2023

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but known and potentially severe side effect of drugs. The recent development of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as ribociclib, has considerably improved the management of hormone receptor positive (HR+) and HER2 negative (HER2-) advanced breast cancer. Here, we present the case of an 83-year-old patient who developed a probable DRESS syndrome induced by ribociclib, presenting with fever, eosinophilia, rash, and hepatic cytolysis. The RegiSCAR score was 4. The symptomatology evolved favorably with topical and systemic corticosteroids, without any sequel. Another CDK4/6 inhibitor, palbociclib, was introduced later without any cross-toxicity and with an excellent therapeutic response for more than 3 years.

show abstract

Section: Introductionmentioning

confidence: 99%